Olverembatinib Clinical Trials
11 recruitingDrug
Phase 23Not Applicable3Phase 12Phase 32Early Phase 11
Showing 1–11 of 11 trials
Recruiting
Not Applicable
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China110 enrolled1 locationNCT07493161
Recruiting
Phase 3
A Study of Olverembatinib in SDH-deficient GIST.
GIST
Ascentage Pharma Group Inc.40 enrolled1 locationNCT06640361
Recruiting
Early Phase 1
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University20 enrolled2 locationsNCT07074496
Recruiting
Not Applicable
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Acute Lymphoblastic LeukemiaPh-Like
Institute of Hematology & Blood Diseases Hospital, China92 enrolled1 locationNCT07454226
Recruiting
Phase 3
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ph+ ALLLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.350 enrolled90 locationsNCT06051409
Recruiting
Phase 1
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Advanced Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center30 enrolled1 locationNCT06401603
Recruiting
Not Applicable
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
Acute Lymphoblastic Leukemia, AdultPhiladelphia Positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China82 enrolled1 locationNCT06481228
Recruiting
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Chronic Myeloid Leukemia
Peking University People's Hospital30 enrolled15 locationsNCT06390306
Recruiting
Phase 1Phase 2
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
CML,Blast Phase
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06757855
Recruiting
Phase 2
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Precursor B-Cell Acute Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University36 enrolled1 locationNCT06754267
Recruiting
Phase 2
Olverembatinib for FGFR1-rearranged Neoplasms
Acute LeukemiaMyeloproliferative Neoplasm
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT05521204